Neurotype Inc.

Neurotype Inc. is a healthcare and information technology startup headquartered in the United States, founded in 2019. The company's slogan, "Brain-based solutions to disarm cravings for precision relapse prevention," encapsulates its core focus. Neurotype Inc. aims to revolutionize the treatment of craving in drug and food addictions through the development of brain sensors and digital therapeutics. Their current focus lies in the creation of an FDA-regulated device that utilizes new neurofeedback technology for personalized prevention of drug craving and relapses in Opioid Use Disorder. In their latest funding round, which took place on 30 September 2023, Neurotype Inc. secured an investment of $328.96K in a Seed Round, with the National Institute on Drug Abuse (NIDA) as the key investor. This injection of capital will likely further the company's groundbreaking work in the neurotechnology space, catering to a pressing need in the realm of addiction treatment. Neurotype Inc.'s pioneering approach, coupled with promising financial backing, positions the company favorably within the burgeoning intersection of healthcare and technology. As the startup continues to develop its innovative solutions, particularly in the realm of precision relapse prevention, it stands as an intriguing prospect for venture capital stakeholders seeking impactful investments in the evolving landscape of healthcare technology.